JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Inclusion Criteria:

• Participants must be able to provide an archived tumor sample

• Histologically or cytologically confirmed advanced colorectal cancer, advanced smallintestinal cancer and advanced appendiceal cancer with KRAS p.G12C mutation

• Must have received at least 1 prior standard therapy

• Must have at least 1 measurable lesion per RECIST v1.1

• Must have adequate organ function

• Must be able to swallow and retain orally administered medication

Exclusion Criteria:

• Has brain metastases, except if treated and no evidence of radiographic progressionor hemorrhage for at least 28 days

• Active infection requiring systemic treatment within 14 days

• Active HIV, HBV or HCV

• Any severe and/or uncontrolled medical conditions

• LVEF<50% assessed by ECHO

• QT interval >470 msec